
- Sana Bouyahia, Head of Project Development Health & Sports, represents Team Nice Côte d’Azur in London from November 16 to 19, 2026, during London Life Sciences Week (November 15 to 20), where London & Partners and Jefferies expect more than 5,000 attendees and 1,300 investors.
- Sana will meet investors, industry leaders and founders, then present the Côte d’Azur health ecosystem to open the way to partnerships and new locations.
- Company milestones include an FDA clearance for Caranx Medical, an application accepted for review in the United States and China for Nicox, a US patent for ExAdEx-Innov and a €50M raise for Median Technologies.
- The CHU de Nice runs a health data warehouse selected under France 2030 and a territorial clinical research entity.
- 3IA Côte d’Azur and the 4D-OMICS platform tie research to AI, while PUI MED’INNOV links laboratories to companies.
- The Lab at Nice Méridia offers 6,858 m², including 1,545 m² of R&D laboratories, with delivery in Q1 2028.
- Eurobiomed members raised €247.6M across the South of France in the first half of 2026, with biotechs taking 60.5%.
Sana Bouyahia takes part in London Life Sciences Week to meet investors, industry leaders and founders, and to present the Côte d’Azur health ecosystem. The mission is part of Team Nice Côte d’Azur’s regular presence at the major international life sciences events of 2026.
A week for the life sciences community
London & Partners organizes the week in partnership with Jefferies. It expects more than 5,000 attendees and over 1,300 investors: venture capital and institutional investors, pharma and medtech executives, academics, start-up founders and healthcare professionals. Topics include genomics, AI, health data and bioengineering.
Medtech and digital health
Caranx Medical, based in Nice, won the world’s first FDA clearance for an AI software that guides heart valve implantation during surgery.
Median Technologies, in Sophia Antipolis, raised €50M in June 2026 for eyonis LCS, its early lung cancer screening solution.
SunWaves-MedTech, headquartered in Nice with R&D in Sophia Antipolis, pairs a proprietary AI with a medical supervision center staffed around the clock.
Circum Life Sciences, a member of France Biotech, is a CDMO for medical devices with resources in Switzerland, France and Tunisia.
Biotech and life sciences
Nicox, in Sophia Antipolis, had its application for NCX 470 accepted for review in the United States, with a PDUFA date of April 30, 2027, and in China.
ExAdEx-Innov, hosted at the Nice Faculty of Medicine, secured a US patent for its 3D models of ex vivo human tissue.
Roca Therapeutics received EMA orphan drug designation for RCT002, the first recognition of radiation maculopathy as a distinct indication.
DimiCare, based in Nice, is a preclinical-stage company developing precision therapies against WHO-priority multidrug-resistant pathogens, and won i-Lab 2025 and the Pépite France prize.
Ariah.bio, the brand of AMK biotech at the Sophia Antipolis Bioparc, analyzes tissue with high-plex imaging and AI, and is a France 2030 laureate working with L’Oréal Advanced Research.
Research and AI
3IA Côte d’Azur draws on Université Côte d’Azur, CNRS, Inserm and Inria. The 4D-OMICS platform, led by Université Côte d’Azur and backed with €6.6M from the French Investments for the Future Program, processes multidimensional data with Aix-Marseille Université, APHM and the Institut Paoli-Calmettes, among others.
PUI MED’INNOV is one of 29 university innovation hubs labeled under France 2030. Led by Université Côte d’Azur with Università di Corsica Pasquale Paoli, Université de Toulon and 11 other partners, it covers Corsica and the Côte d’Azur.
Clinical and data infrastructure
At the CHU de Nice, the EDS Méditerranée health data warehouse, a France 2030 winner, connects to the region’s supercomputers and to 3IA. The AZUR clinical research entity was signed in late March 2026. In 2024, the hospital recorded 920 publications and 345 ongoing industry trials, and it holds 28 patents.
Funding
Eurobiomed members raised €247.6M across the South of France in the first half of 2026, including €228.8M in private funding. Biotechs took 60.5%, medtechs 26% and digital health 13.5%.
Location: the Lab at Nice Méridia
The first stone of the Lab was laid on October 19, 2026. The building offers 6,858 m², made up of 5,313 m² of offices and 1,545 m² of R&D laboratories, for a €30M private investment. Delivery is scheduled for Q1 2028.
More than 40% of the office space is let, with SMABTP and Altarea as first occupiers. The laboratories, aimed at health and medtech companies, are still to be let. The site is close to tramway line 3 and will connect to the district’s geothermal network.
Get in touch
Biotech, medtech and digital health companies looking for a foothold in Europe or for R&D space can contact Sana Bouyahia, in London that week or beforehand.
Practical information
🗓️ November 15 to 20, 2026 (Team Nice Côte d’Azur on site November 16 to 19)
📍 London
🏛️ London & Partners, in partnership with Jefferies